Avalyn Pharma Inc. (AVLN) SEC Filings & Earnings Calls
EquiReason read 11 Avalyn Pharma Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-16 — Appointment of Robert Meyer, M.D. to the Board of Directors as a Class II director, effective September 15, 2026. Dr. Meyer brings extensive FDA and regulatory experience..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 1.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
12 Aug 202610-QQ2 2026 net loss widened to $28.9M from $20.2M YoY, driven by increased R&D spending; IPO in May 2026 raised $316.6M net.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q2-2026 | $-29M | +43% y/y |
| Research and development expense · Q2-2026 | $25M | +38% y/y |
| General and administrative expense · Q2-2026 | $7M | +68% y/y |
| Cash and cash equivalents · 2026-06-30 | $264M | +331% y/y |
| Accumulated deficit · 2026-06-30 | $-321M | +47% y/y |
| Diluted earnings per share · Q2-2026 | $-0.98 | -94% y/y |
| Cash and investments · 2026-06-30 | $414M | |
| Operating cash flow · H1-2026 | $-56M | +40% y/y |
Risks flagged
Clinical-stage development risk
“We are a clinical-stage biopharmaceutical company and have incurred significant operating losses since inception and anticipate that we will continue to incur significant operating losses for the foreseeable future.” · word for word
Dependence on lead candidates
“We are substantially dependent on the success of our lead candidates, AP01 and AP02.” · word for word
Need for additional funding
“We will need substantial additional funding. We may be unable to raise capital on acceptable terms, if at all.” · word for word
12 Aug 20268-K · 2.02Cash, cash equivalents and marketable securities $414M; Net loss $-29M (+43% y/y); R&D expenses $25M (+38% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q2-2026 | $414M | |
| Net loss · Q2-2026 | $-29M | +43% y/y |
| R&D expenses · Q2-2026 | $25M | +38% y/y |
| G&A expenses · Q2-2026 | $7M | +69% y/y |
| Enrolled patients in MIST trial · Q2-2026 | 398 |
Risks flagged
Increasing net loss and operating expenses
“Net loss increased 43.1% to $28.9M; R&D up 38%; G&A up 69.2%”
1 Jul 20268-K · 1.01Avalyn Pharma amended a sublease with CRISPR Therapeutics, expanding premises from ~8,774 to ~13,708 sq ft and increasing future minimum lease payments by ~$924,000.open
Risks flagged
No material risk identified.
“Routine sublease amendment.”
17 Jun 20268-K · 7.01Enrolled patients 375open
Figures in the filing · each found in the filing text
| Enrolled patients · AP01 · Q2-2026 | 375 |
Risks flagged
Clinical-stage risk; no approved products.
“Clinical-stage biopharmaceutical company; forward-looking statements include risks of trial delays and unexpected data.”
3 Jun 202610-QCash, cash equivalents and marketable securities $123M; Net loss $-27M; Net loss per share $-21.83open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $123M | |
| Net loss · Q1-2026 | $-27M | |
| Net loss per share · Q1-2026 | $-21.83 | |
| Research and development expense · Q1-2026 | $23M | |
| General and administrative expense · Q1-2026 | $5M | |
| Operating cash flow · Q1-2026 | $-30M | |
| Free cash flow · Q1-2026 | $-30M | |
| Cash and cash equivalents · Q1-2026 | $92M | |
| Marketable securities · Q1-2026 | $31M | |
| Accumulated deficit · Q1-2026 | $-292M |
Risks flagged
Clinical-stage biotech with no approved products
“We are a clinical-stage biopharmaceutical company and have incurred significant operating losses since inception and anticipate that we will continue to incur significant operating losses for the foreseeable future.” · word for word
Dependence on lead candidates AP01 and AP02
“We are substantially dependent on the success of our lead candidates, AP01 and AP02.” · word for word
Significant operating losses and accumulated deficit
“We have incurred significant operating losses since inception and anticipate that we will continue to incur significant operating losses for the foreseeable future.”
Need for substantial additional funding
“We will need substantial additional funding. We may be unable to raise capital on acceptable terms, if at all.” · word for word
Clinical trial delays and uncertainties
“If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.” · word for word
3 Jun 20268-K · 2.02Net loss $-27M; Cash, cash equivalents, and marketable securities $123M; R&D expenses $23Mearningsopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-27M | |
| Cash, cash equivalents, and marketable securities · Q1-2026 | $123M | |
| R&D expenses · Q1-2026 | $23M | |
| G&A expenses · Q1-2026 | $5M | |
| IPO gross proceeds · Q2-2026 | $345M |
Risks flagged
Clinical-stage biopharma with no approved products; reliance on pipeline success.
“Clinical-stage biopharmaceutical company; no revenue from product sales.”
Avalyn Pharma Inc. — questions
- What did Avalyn Pharma Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 8-K on 2026-09-16 — Appointment of Robert Meyer, M.D. to the Board of Directors as a Class II director, effective September 15, 2026. Dr. Meyer brings extensive FDA and regulatory experience.
Every figure on this page comes from Avalyn Pharma Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.